Attention-deficit hyperactivity disorder atomoxetine

Gibson AP, Bettinger TL, Patel NC, Crismon ML (2006) Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Ann Pharmacother 40 1134-1142... 

Arginine vasopressin (AVP), 281 Aromatase, 272 Arousal, 133-134 Atomoxetine, 425 Atropine, 308, 399-300 Attention, 117, 125, 127, 130-134, 137 Attentional performance, 146, 160-161 Attention deficit hyperactive disorder (ADHD), 117-118... 

APPROVED TREATMENTS FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER AMPHETAMINE (ADDERALL ), METHYLPHENIDATE (RITALIN ), AND ATOMOXETINE (STRATERRA )... 

Michelson, D., Paries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, RR., Spencer, T. (2001) Atomoxetine in the treatment of children and adolescents with attention deficit / hyperactivity disorder a randomized place to controlled, dose response study. Pediatrics 108 E83. 

Spencer, X, Biederman, J., Heiligenstein, J., Wilens, X, Paries, D., Prince, J., Earaone, S.V., Rea, J., Witcher, J., and Zeras, S. (2001) An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 11 ... 

Adderall XR (package insert). Wayne, PA, Shire US Inc, 2004 Angrist B, d Hollosy M, Sanfilipo M, et al Central nervous system stimulants as symptomatic treatments for AIDS-related neuropsychiatric impairment. J Clin Psychophamiacol 12 268—272, 1992 Arnold LE, Lindsay RL, Connors CK, et al A douhle-hlind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention-deficit hyperactivity disorder. I Am Acad Child Adolesc Psychiatry 14 542—554, 2004 Belle DJ, Ernest CS, Sauer JM, et al Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. I Clin Pharmacol 42 1219-1227, 2002... 

Bymaster FP, Katner JS, Nelson DL, et al Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat a potential mechanism for efficacy in attention-deficit/hyperactivity disorder. Neuropsychopharmacology 27 699-711, 2002... 

Kelsey DK, Sumner CR, Casat CD, et al Once-daily atomoxetine for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior a double-blind, placebo-controlled trial. Pediatrics 114 1—8, 2004... 

Kratochvil CJ, Bohac D, Harrington M, et al An open-label trial of atomoxetine in pediatric attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 11 167—170, 2001... 

Michelson D, Allen AJ, Busner J, et al Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder a randomized, placebo-controlled study. Am J Psychiatry 159 1896-1901, 2002... 

Spencer T, Biederman J, Wilens T, et al Effectiveness and tolerability of atomoxetine in adults with attention deficit hyperactivity disorder. Am J... 

Suicidal ideation in Child and Adolescents—STRATTERA (atomoxetine) increased the risk of suicidal ideation in short-term studies in children or adolescents with Attention-Deficit Hyperactivity Disorder (ADHD). Anyone considering the use of STRATTERA in a child or adolescent must balance this risk with the clinical needs. Patients who are started on therapy should be monitored closely for suicidality (suicidal thinking and behavior), clinical worsening, or unusual changes in behavior. 

Kratochvil CJ, Vaughan BS, Harrington MJ, Burke WJ. Atomoxetine a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Pharmacother 2003 4(7) 1165-74. 

Atomoxetine is a selective NE reuptake blocker used in attention deficit hyperactivity disorder. 

Atomoxetine is a psychotherapeutic agent that inhibits the presynaptic transport of norepinephrine. It is indicated in the treatment of attention-deficit/hyperactivity disorder (ADHD). 

OTHER THERAPEUTIC USES OE THESE DRUGS The various antidepressant agents have found broad utility in other disorders that may not be related psychobiologicaUy to the mood disorders. Current applications include rapid but temporary suppression of enuresis with low (e.g., 25 mg) pre-bedtime doses of tricyclic antidepressants, including imipramine and nortriptyline, by uncertain mechanisms in children and in geriatric patients, as well as a beneficial effect of duloxetine on urinary stress incontinence. Antidepressants have a growing role in attention-deficit/hyperactivity disorder in children and adults, for which imipramine, desipramine, and nortriptyline appear to be effective, even in patients responding poorly to or who are intolerant of the stimulants (e.g., methylphenidate). Newer NE selective reuptake inhibitors also may be useful in this disorder atomoxetine is approved for this application. Utility of SSRIs in this syndrome is not established, and bupropion, despite its similarity to stimulants, appears to have limited efficacy. 

R-(-)-atomoxetine, a 2-methylphenoxyphenylpropylamine, was marketed in 2003 as a nonstimulant treatment for attention-deficit hyperactivity disorder (ADHD) in both adults and children and for treatment of adult depression. The 2-methyl substitution (c.f., nisoxetine) (Fig. 21.8) confers selectivity for inhibiting NE reuptake (Table 21.6) (21,22,45). The R-enantiomer is 10 times more potent than the S-enantiomer as a NET reuptake inhibitor. Atomoxetine has a low propensity for anticholinergic and adverse cardiovascular effects. 

Which statement is the scientific rationale for prescribing atomoxetine (Strattera), a norepinephrine reuptake inhibitor, for a child diagnosed with attention deficit-hyperactivity disorder (ADHD) ... 

Torres A, Whitney J, Rao S, Tilley C, Lobel R, Gonzalez-Heydrich J. Tolerability of atomoxetine for treatment of pediatric attention-deficit/hyperactivity disorder in the context of epilepsy. Epilepsy Behav 2011 20(1) 95-102. 

Martenyi F, Zavadenko NN, Jarkova NB, Yarosh AA, Soldatenkova VO, Bardenstein LM, Kozlova lA, Neznanov NG, Maslova OI, Petrukhin AS, Sukchotina NK, Zykov VP. Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder a 6-week, randomized, placebo-controlled, double-blind trial in Russia. Eur Child Adolesc Psychiatry 2010 19(1) 57-66. 

Banerjee S, Ayyash HF. Does atomoxetine increase the risk of aggression and hostility in children with attention deficit hyperactivity disorder Arch Dis Child Educ Pract Ed 2008 93(4) 131-2. 

---